The USA-based company is focused on leveraging core expertise in drug discovery and development and kinase inhibition to develop novel, small molecule therapies to help people impacted by under-served immuno-inflammatory conditions.

The company's proprietary KINect technology platform is used to generate clinical candidates for difficult to drug kinases with novel approaches.